[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639759":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":33,"locations":39,"responsibleParty":98,"collaborators":11,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":102,"sex":108,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":11,"studyType":114,"phases":115,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"Oculis","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Privosegtor","EXPERIMENTAL",null,[13,14],"Drug: Privosegtor","Drug: Methylprednisolone",{"label":16,"type":17,"description":11,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR",[14,19],"Other: Placebo",[21,25,29],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Privosegtor (OCS-05) 3 mg\u002Fkg\u002Fday IV for 5 treatment days",[9],{"type":22,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Methylprednisolone","Methylprednisolone 1 g\u002Fday IV for 5 treatment days",[16,9],{"type":30,"name":16,"description":31,"armGroupLabels":32,"otherNames":11},"OTHER","0.9% sodium chloride (NaCl) solution IV for 5 treatment days",[16],[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Chief Development Officer","CONTACT","617-928-5886","info@oculis.com",[40,59,69,84],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Kahana Oculoplastic and Orbital Surgery","RECRUITING","Livonia","Michigan","48152","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-83.35271,42.36837,{"lat":52,"lon":51},[55],{"name":56,"role":36,"phone":57,"phoneExt":11,"email":58},"Dr. Victoria Williams","248-800-1177","kcrc@mioculoplastics.com",{"facility":60,"status":42,"city":61,"state":62,"zip":63,"country":46,"countryCode":47,"cosmosGeoPoint":64,"geoPoint":68,"contacts":11},"Medical University of South Carolina, Storm Eye Institute","Charleston","South Carolina","29425",{"type":49,"coordinates":65},[66,67],-79.93275,32.77632,{"lat":67,"lon":66},{"facility":70,"status":42,"city":71,"state":72,"zip":73,"country":46,"countryCode":47,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"UT Southwestern Medical Center (Ophthalmology CRU)","Dallas","Texas","75390",{"type":49,"coordinates":75},[76,77],-96.80667,32.78306,{"lat":77,"lon":76},[80],{"name":81,"role":36,"phone":82,"phoneExt":11,"email":83},"Ruben Jauregui, MD","214-645-2014","OphthaResearch@UTSouthwestern.edu",{"facility":85,"status":42,"city":86,"state":72,"zip":87,"country":46,"countryCode":47,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Neuro-Eye Clinical Trials","Houston","77074",{"type":49,"coordinates":89},[90,91],-95.36327,29.76328,{"lat":91,"lon":90},[94],{"name":95,"role":36,"phone":96,"phoneExt":11,"email":97},"Mirna Maldonado","713-894-4393","Rtang@neuroeye.com",{"type":99,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100639759","phase-3-privosegtor-investigation-in-optic-neuropathies-efficacy-evaluation-research-100639759",false,"NCT07623668","Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research","A Randomized, Double-masked, Placebo-controlled Study Assessing the Efficacy and Safety of Privosegtor (OCS-05) in Patients With Optic Neuritis (ON)","PIONEER-1","Key Inclusion Criteria:\n\n* Adult men and women (aged 18 to 50 years) with the first episode of ON in the study eye, associated with unilateral visual loss.\n* Onset of visual loss symptoms in the previous 12 days before first administration of study treatment.\n\nKey Exclusion Criteria:\n\n\\- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety","ALL","18 Years","50 Years",{"count":112,"type":113},210,"ESTIMATED","INTERVENTIONAL",[116],"PHASE3","The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON).\n\nResearchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).",[119],"Optic Neuritis",[119,121,122,123,124,125,126,127,128,129,9,130],"ON","AON","Optic Neuropathy","Multiple Sclerosis","MS","Vision Loss","LCVA","Low Contrast Visual Acuity","Low Contrast Sensitivity","OCS-05","2026-08-13",{"date":133,"type":134},"2026-08-14","ACTUAL",{"date":136,"type":134},"2026-05-28",{"date":138,"type":113},"2028-12",{"name":5,"class":6},4]